CompanyGraph
China Traditional Chinese Medicine Holdings Co. Limited
0570 · HKEX · Hong Kong
Price data from its WSG listing on XSTU, quoted in EUR
china-tcm.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.5B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.73BHKD1.50B · vs all stocks (USD)
Revenue (TTM)
17.16BHKD2.19B · vs all stocks (USD)
Profit Margin
-2.32%Beta
0.7520xvs all stocks
52-Week Change
-38.12%vs all stocks
Market Capitalization
11.73BHKD1.50B · vs all stocks (USD)
Enterprise Value
8.14BHKD1.04B · vs all stocks (USD)
Forward P/E
8.94xPrice to Sales (TTM)
0.4799xPrice to Book (MRQ)
0.2970xEnterprise to Revenue
0.4740xEnterprise to EBITDA
4.60xProfit Margin
-2.32%Operating Margin
3.60%Return on Assets (TTM)
0.84%Return on Equity (TTM)
-1.95%Revenue (TTM)
17.16BHKD2.19B · vs all stocks (USD)
Revenue per Share (TTM)
2.93HKDUpdated Aug 19, 2026Quarterly Revenue Growth
-10.40%Gross Profit (TTM)
8.25BHKD1.05B · vs all stocks (USD)
EBITDA (TTM)
1.35BHKD172.39M · vs all stocks (USD)
Net Income (TTM)
-398.09MHKD-50.75M · vs all stocks (USD)
Operating Cash Flow (TTM)
2.65BHKD338.42M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.09BHKD266.44M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
2.56BCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0679CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0679CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
5.04BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
5.04BSharesFY2025 · Dec 31, 2025Operating Cash Flow
458.86MCNYFY2025 · Dec 31, 2025Free Cash Flow
140.51MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.87BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-368.23MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.45MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-478.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.30BCNYFY2025 · Dec 31, 2025Capital Expenditures
-318.35MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.40MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Other Investing Activity
114.29MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-204.06MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.30BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.80BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-396.45MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.89BCNYFY2025 · Dec 31, 2025Shares Outstanding
5.04BSharesUpdated Aug 19, 2026Float Shares
2.75BSharesUpdated Aug 19, 2026% Held by Insiders
33.46%vs all stocks
% Held by Institutions
17.85%vs all stocks
Total Cash (MRQ)
5.97BHKD761.33M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.02HKDUpdated Aug 19, 2026Total Debt (MRQ)
2.90BHKD369.99M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1083xCurrent Ratio (MRQ)
2.29xBook Value per Share (MRQ)
4.73HKDUpdated Aug 19, 2026Total Assets
32.35BCNY4.80B · vs all stocks (USD)
Total Current Assets
17.71BCNYFY2025 · Dec 31, 2025Total Liabilities
9.32BCNYFY2025 · Dec 31, 2025Total Non-current Assets
14.64BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.59BCNYFY2025 · Dec 31, 2025Total Current Liabilities
7.73BCNYFY2025 · Dec 31, 2025Cash
3.94BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.94BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.11BCNYFY2025 · Dec 31, 2025Accounts Receivable
8.38BCNYFY2025 · Dec 31, 2025Inventory
3.71BCNYFY2025 · Dec 31, 2025Accounts Payable
2.21BCNYFY2025 · Dec 31, 2025Short-term Debt
2.23BCNYFY2025 · Dec 31, 2025Long-term Debt
260.22MCNYFY2025 · Dec 31, 2025Common Stock (Book)
11.98BCNYFY2025 · Dec 31, 2025Retained Earnings
7.79BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
23.03BCNY3.42B · vs all stocks (USD)
52-Week Low
1.32HKDUpdated Aug 19, 202652-Week High
2.68HKDUpdated Aug 19, 202652-Week Change
-38.12%vs all stocks
Beta
0.7520xvs all stocks
50-Day MA
1.44HKDUpdated Aug 19, 2026200-Day MA
1.86HKDUpdated Aug 19, 2026Avg 10-Day Volume
8.07MSharesUpdated Aug 19, 2026Avg 30-Day Volume
11.52MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0800HKDUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.5B, above the global median of $1.15BNotable
Market cap (USD): 1,495,893,500.979Global Median: 1,146,734,693.424
Revenue is $2.19B, above the global median of $520.53MNotable
Revenue (USD): 2,187,687,426.754Global Median: 520,528,949.311
Levered free cash flow is $266.44M, above the global median of $16.24MNotable
Levered free cash flow (USD): 266,441,535.988Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Aurora Optoelectronics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Fushine Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow